Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00813124 · ClinicalTrials.gov registry record · Phase 2
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00813124: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00813124 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00813124, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if Vidaza (azacitidine) when given to patients with CML after an donor stem cell transplant will increase the likelihood of achieving a complete remission of CML.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Azacitidine
- DRUG Thymoglobulin
- PROCEDURE Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-12 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00813124
The ClinicalTrials.gov registry entry for NCT00813124 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00813124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00813124 about?
NCT00813124 is a clinical study titled "Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)". The goal of this clinical research study is to learn if Vidaza (azacitidine) when given to patients with CML after an donor stem cell transplant will increase the likelihood of achieving a complete remission of CML.
What is the current status of trial NCT00813124?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-12. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00813124?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Azacitidine (DRUG), Thymoglobulin (DRUG), Stem Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00813124?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.